Eli Lilly has skyrocketed due to its strength in the high-growth obesity drug market. One biotech company in particular may ...

Maybe just to add to that, OUS as well, we continue to advance or engage new countries that we are going to be launching ...

By Sabrina Valle NEW YORK, Jan 20 (Reuters) - Abivax Chief Executive Marc de Garidel dismissed as "noise" reports in the ...

We look at the Novo Nordisk A/S outlook for 2026: new CEO focus, oral Wegovy edge vs Eli Lilly, and double-digit growth ...

Eli Lilly (LLY) heads into 2026 with GLP-1 pricing and competition risks; oral GLP-1 race heats up and downside looms.

Former Apple India marketing leader, Pranav Shroff, moves to healthcare with Eli Lilly, after two decades across technology, ...

The choice isn't that hard.

Indiana Attorney General Todd Rokita appeared on Hammer and Nigel to discuss his recent lawsuit against Eli Lilly, centering on the high cost of insulin and allegations of unfair pricing practices.

Eli Lilly is getting its hands on a promising pipeline candidate thanks to an acquisition. The stock may not gain much more ...

What happens with Eli Lilly's GLP-1 shot now that Novo Nordisk has come out with a GLP-1 pill?

Novo Nordisk oral Wegovy records 3,071 prescriptions in four days. Shares jump 6.5% as Eli Lilly oral weight loss drug awaits ...

SAN FRANCISCO, Jan 12 (Reuters) - Nvidia and U.S. pharma giant Eli Lilly will spend $1 billion building a new joint research ...